Cargando…
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
BACKGROUND: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking. OBJECTIVES: To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360014/ https://www.ncbi.nlm.nih.gov/pubmed/33544917 http://dx.doi.org/10.1111/bjd.19863 |
_version_ | 1783737656620875776 |
---|---|
author | Prens, L.M. Bouwman, K. Aarts, P. Arends, S. van Straalen, K.R. Dudink, K. Horváth, B. Prens, E.P. |
author_facet | Prens, L.M. Bouwman, K. Aarts, P. Arends, S. van Straalen, K.R. Dudink, K. Horváth, B. Prens, E.P. |
author_sort | Prens, L.M. |
collection | PubMed |
description | BACKGROUND: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking. OBJECTIVES: To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients with HS and to identify predictors for drug survival. METHODS: A retrospective multicentre study was performed in two academic dermatology centres in the Netherlands. Adult patients with HS using biologics between 2008 and 2020 were included. Drug survival was analysed with Kaplan–Meier survival curves and predictors of survival with univariate Cox regression analysis. RESULTS: The overall drug survival of adalimumab (n = 104) at 12 and 24 months was 56·3% and 30·5%, respectively, which was predominantly determined by infectiveness. Older age (P = 0·02) and longer disease duration (P < 0·01) were associated with longer survival time. For infliximab (n = 44), overall drug survival was 58·3% and 48·6% at 12 and 24 months, respectively, and was predominantly determined by infectiveness and side‐effects. Surgery during treatment was associated with a longer survival time (P = 0·01). CONCLUSIONS: Survival rates were comparable for adalimumab and infliximab at 12 months, and were mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival. |
format | Online Article Text |
id | pubmed-8360014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83600142021-08-17 Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study Prens, L.M. Bouwman, K. Aarts, P. Arends, S. van Straalen, K.R. Dudink, K. Horváth, B. Prens, E.P. Br J Dermatol Original Articles BACKGROUND: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking. OBJECTIVES: To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients with HS and to identify predictors for drug survival. METHODS: A retrospective multicentre study was performed in two academic dermatology centres in the Netherlands. Adult patients with HS using biologics between 2008 and 2020 were included. Drug survival was analysed with Kaplan–Meier survival curves and predictors of survival with univariate Cox regression analysis. RESULTS: The overall drug survival of adalimumab (n = 104) at 12 and 24 months was 56·3% and 30·5%, respectively, which was predominantly determined by infectiveness. Older age (P = 0·02) and longer disease duration (P < 0·01) were associated with longer survival time. For infliximab (n = 44), overall drug survival was 58·3% and 48·6% at 12 and 24 months, respectively, and was predominantly determined by infectiveness and side‐effects. Surgery during treatment was associated with a longer survival time (P = 0·01). CONCLUSIONS: Survival rates were comparable for adalimumab and infliximab at 12 months, and were mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival. John Wiley and Sons Inc. 2021-05-04 2021-07 /pmc/articles/PMC8360014/ /pubmed/33544917 http://dx.doi.org/10.1111/bjd.19863 Text en © 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Prens, L.M. Bouwman, K. Aarts, P. Arends, S. van Straalen, K.R. Dudink, K. Horváth, B. Prens, E.P. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study |
title | Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
|
title_full | Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
|
title_fullStr | Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
|
title_full_unstemmed | Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
|
title_short | Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
|
title_sort | adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360014/ https://www.ncbi.nlm.nih.gov/pubmed/33544917 http://dx.doi.org/10.1111/bjd.19863 |
work_keys_str_mv | AT prenslm adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy AT bouwmank adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy AT aartsp adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy AT arendss adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy AT vanstraalenkr adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy AT dudinkk adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy AT horvathb adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy AT prensep adalimumabandinfliximabsurvivalinpatientswithhidradenitissuppurativaadailypracticecohortstudy |